European Commission EVP Margrethe Vestager (Photo by Monasse T/ANDBZ/Abaca/Sipa USA/Sipa via AP Images)

September 6, 2022 07:27 AM EDTUpdated 09:55 AM

Updated: EU swats down Illumina's $8B Grail acquisition days after FTC lost antitrust case

Max Gelman

Senior Editor

European regulators blocked Illumina’s $8 billion acquisition of Grail on Tuesday, dealing a whiplash blow to the biotech just days after it prevailed over an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: EU swats down Illumina's $8B Grail acquisition days after FTC lost antitrust case

Max Gelman

Senior Editor

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Merck returns to lucrative eye disease market in up to $3B deal for EyeBio

Biohaven’s autoimmune drug disappoints investors in study of healthy volunteers

AstraZeneca reveals early data for oral PCSK9, touts PK edge over Merck’s drug

Bristol Myers pays $80M to license another Prothena neuroscience candidate

Ikena Oncology weighs ‘strategic options’ as it drops cancer asset, trims headcount to save cash

A novel study insight analytics (SIA) methodology improves PANSS data quality and signal detection in a global ...

Up­dat­ed: EU swats down Il­lu­mi­na's $8B Grail ac­qui­si­tion days af­ter FTC lost an­titrust case

Senior Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Updated: EU swats down Illumina's $8B Grail acquisition days after FTC lost antitrust case